J Neurosci 2002 Nov 1;22(21):9221-7
Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C.
Biologie des Interactions Neurones-Glie, Institut National de la Sante et de la Recherche Medicale Unite 495, Paris cedex 13, France, and Federation de Neurologie, Universite Pierre et Marie Curie, Hopital de la Salpetriere, 75651 Paris cedex 13, France.
In multiple sclerosis, myelin repair is generally insufficient despite the relative survival of oligodendrocytes within the plaques and the recruitment of oligodendrocyte precursors.
Promoting remyelination appears to be a crucial therapeutic challenge.
Using a newly developed enzymatic index of myelination, we screened different neurotrophic factors for their ability to enhance myelination.
Neurotrophins [NGF, neurotrophin-3 (NT-3), NT-4/5, BDNF], glial cell line-derived neurotrophic factor (GDNF)-related factors (GDNF, neurturin), and growth factors such as PDGF-AA, FGF-2, and insulin did not increase myelinogenesis.
In contrast, among factors belonging to the CNTF family, CNTF, leukemia inhibitory factor, cardiotrophin-1, and oncostatin M induced a strong promyelinating effect.
We provide evidence that CNTF acts on oligodendrocytes by favoring their final maturation, and that this effect is mediated through the 130 kDa glycoprotein receptor common to the CNTF family and transduced through the Janus kinase pathway.
Our results demonstrate a novel role for neurotrophic factors of the CNTF family and raise the possibility that these factors might be of therapeutic interest to promote remyelination in multiple sclerosis.